SAN DIEGO, June 15, 2020 – ProSciento, Inc., a clinical research organization (CRO) exclusively focused on NASH, diabetes, obesity, and related metabolic diseases, announced today that its clinical research unit (CRU) in San Diego has implemented on-site rapid COVID-19 antigen and antibody testing for essential staff and clinical study participants.
“Most of our study participants are considered higher risk populations for COVID-19 complications, including individuals with diabetes, obesity and hypertension. We have an obligation to our study participants and staff to enact safety measures to the fullest possible extent. As such, we established an internal mandate at our CRU for on-site COVID-19 testing prior to the relaunch of essential clinical research activities,” said Marcus Hompesch, MD, ProSciento’s Chief Executive Officer. “We’re pleased to have now implemented point-of-care COVID-19 antigen and antibody testing protocols, in addition to the ancillary safety measures that will remain in place.”
In addition to testing, existing safety measures at ProSciento’s CRU include:
- Six-foot social distancing and face covering protocol throughout facility
- Clinic zoning restricted to 10 individuals per area with independent entrance, exit and air flow system
- Full personal protective equipment (PPE) for clinical staff
- MERV-13 HVAC airflow filtration system (HVAC system used in hospital surgical rooms)
- COVID-19 symptom and exposure monitoring triage prior to entry for all
- Daily medical grade sanitation of clinic
“ProSciento’s CRU is widely recognized for its specialized methodologies and expertise in metabolic clinical research, including being the only center in the U.S. that offers high capacity automated glucose clamp procedures. At this clinic alone, ProSciento has conducted nearly 300 early phase clinical studies for metabolic diseases, including more phase I/II diabetes clinical trials than any other U.S. provider,” continued Dr. Hompesch. “With a profound focus on utilizing advanced clinical research methods, it is of critical importance that our CRU set a high bar for patient and staff safety, which now includes antigen and antibody testing.”
For more information or questions about ProSciento’s COVID-19 safety and response measures for CRU and multi-site clinical studies, please contact COVIDemail@example.com.
About ProSciento, Inc.
ProSciento is a leading specialized clinical research organization (CRO) exclusively focused on NASH, diabetes, obesity, and related metabolic diseases. ProSciento works with biopharma companies worldwide to support their outsourced clinical research needs with comprehensive and customized services for multinational, early development clinical trial programs. Founded in 2003, ProSciento has a global network for more than 220 sites, including a state-of-the-art specialized clinical unit in Southern California, and is widely recognized for its scientific expertise, depth of services, and contributions to the development of many approved metabolic drugs and devices on the market globally. For more information, please visit www.prosciento.com.
For business development inquiries, please contact:
For media inquiries, please contact:
Senior Director, Corporate Communications, ProSciento, Inc.
For clinical trial enrollment inquires:
Tel: +1 (866) 308-7427